Europe
It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.
Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of Spanish media group Intereconomia.
Boston-based PureTech Health inked a multi-year collaboration deal with Swiss-based Roche to advance PureTech’s milk-derived exosome platform technology for oral dosing of Roche’s antisense oligonucleotide platform.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Kite, a Gilead company based in Santa Monica, California, signed an agreement with Utrecht, Netherlands-based Gadeta BV. The companies will work on discovering and developing novel cancer immunotherapies based on gamma-delta T-cell receptors (TCRs).
Roche’s Tecentriq, in combination with chemotherapy, hit its co-primary endpoint of progression-free survival in a Phase III trial for non-small cell lung cancer patients. But, the Swiss pharma giant said the combination has so far failed to achieve statistical significance in overall survival, a co-primary trial endpoint.
Galapagos and MorphoSys signed an exclusive development and commercialization deal with Swiss-based Novartis.
Recent studies in early diagnostics underline just how much focus medical technology companies are making on developing different modalities for very early cancer diagnosis. Here are just some recent examples.
One year after Vivek Ramaswamy launched Urovant Sciences to develop urological therapies, the company is now seeking $150 million from an initial public offering.
The U.S. Food and Drug Administration (FDA) was busy during the first half of this year with more than 20 novel drug approvals. Of those approvals, one-third came in June.
PRESS RELEASES